Nasometin Control (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. The resulting complex alters gene expression, suppressing inflammatory cytokines and reducing swelling, mucus production, and vascular leakage, which together alleviate the nasal inflammation characteristic of allergic rhinitis.

The specific dosing regimen for Nasometin Control is determined by the prescribing healthcare professional. Typically, the prescriber will advise the number of sprays per nostril and the frequency based on the patient’s age, severity of symptoms, and response to therapy.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing it to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasometin Control delivers mometasone furoate, which is considered a high‑potency nasal corticosteroid. Compared with lower‑potency options such as fluticasone or budesonide, it may achieve symptom control with fewer sprays, but the choice depends on individual response, tolerability, and prescriber preference.

Store Nasometin Control at room temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Nasometin Control is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of times while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious adverse events, although rare, include nasal septal perforation, adrenal suppression with prolonged use, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they notice persistent nosebleeds, unusual fatigue, or signs of a severe allergic response.

Nasometin Control should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, in children younger than two years unless specifically advised by a specialist, and in patients with untreated acute nasal infections.